NASDAQ$WGS

GeneDx Holdings Corp · Q3 2021 earnings

Q3 2021 earnings ·

Headline financials

Total Revenue

$43.2M

No prior period
EPS

$0.15

No prior period
Capital Expenditures

-$4.34M

No prior period
Free Cash Flow

$27M

No prior period
Net Income

$31.4M

No prior period
Operating Income

-$89.6M

No prior period
Gross Profit

-$15.6M

No prior period
Cash & Equivalents

$461M

No prior period
Total Assets

$603M

No prior period

Revenue & EPS history

GeneDx Holdings Corp · Revenue · Quarterly

$43.2M

Q3 2021
Beat estimate in 1 of 2 quarters(50%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 14 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

-0.2%

Avg return

Earnings day

-7.5%

Avg return

5 days after

-10.6%

Avg return

30 days after

36%

5 / 14 earnings

Positive

+49.9%

Q3 2024

Best reaction

-42.8%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+3.8%-37.6%-18.8%
Q4 2025+6.1%-2.9%-18.4%
Q3 2025+5.2%+4.8%+26.7%
Q1 2025-42.8%-43.4%-39.1%
Q3 2024+49.9%+38.7%+41.7%
Q2 2024-10.6%-10.7%-3.6%
Q1 2024-0.7%+77.4%+90.9%
Q3 2023-1.1%-20.7%-2.2%
Q2 2023-0.6%-21.2%-34.1%
Q1 2023-5.6%-22.2%-24.3%
Q3 2022-12.2%-39.0%-70.8%
Q2 2022-1.2%-51.0%-58.8%
Q1 2022+10.3%+32.1%+1.9%
Q3 2021-2.5%-9.2%-39.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro